Overview
CAI market data
Price History
CAI price chart
Valuation & Profitability
- P/E (TTM)
- 59.62 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.41 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.44 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 10.6% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.19 – $42.50 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $6.3B · P/B 13.19 · P/S 6.33.
Company News
Evercore ISI Group Maintains Outperform on Caris Life Sciences, Raises Price Target to $26Benzinga · Aug 6, 2026, 2:52 PM
Caris Life Science shares are trading higher after the company reported better-than-expected Q2 sales guidance and raised its FY26 sales guidance above estimates.Benzinga · Aug 6, 2026, 11:50 AM
Caris Life Science sshares are trading higher after the company reported better-than-expected Q2 sales guidance and raised its FY26 sales guidance above estimates.Benzinga · Aug 5, 2026, 8:49 PM
Caris Life Sciences Raises FY2026 Sales Guidance from $1.000B-$1.020B to $1.030B-$1.040B vs $1.003B EstBenzinga · Aug 5, 2026, 8:25 PM
Caris Life Sciences Q2 Sales $263.712M Beat $238.125M EstimateBenzinga · Aug 5, 2026, 8:14 PM
8-K filing — Caris Life Sciences, Inc. (CAI)SEC EDGAR · Aug 5, 2026, 8:12 PM
Caris Life Sciences To Offer In-House PTEN Immunohistochemistry Testing After Recent FDA Approval Of Biomarker-Guided Therapy And Diagnostic AssayBenzinga · Jul 14, 2026, 12:36 PM
Caris Life Sciences Announces Dual Listing Of Common Shares On NYSE Texas, Effective June 17Benzinga · Jun 16, 2026, 12:40 PM
Caris Life Sciences Announces $100M Buyback PlanBenzinga · Jun 8, 2026, 12:40 PM
Stock Market Today: Nasdaq 100 Slips As Broadcom Plunges, Bitcoin Hits 4-Month LowsBenzinga · Jun 4, 2026, 6:15 PM